PUT - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Borsa Italiana 21:04:59 31/05/2024 BST | ||
| 3.4 EUR | -4.49% |
|
| 1 month | -8.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 3.44 | -3.37% |
| 30/05/24 | 3.56 | -1.11% |
| 29/05/24 | 3.6 | +1.41% |
| 28/05/24 | 3.55 | +1.14% |
| 27/05/24 | 3.51 | +4.46% |
Real-time Borsa Italiana
Last update May 31, 2024 at 09:04 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| F45381 | |
| ISIN | DE000VD05D85 |
| Date issued | 11/03/2024 |
| Strike | 1,176 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.83 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.71 € |
|---|---|
| Lowest since issue | 3.23 € |
| Spread | 0.13 € |
| Spread % | 3.76% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- F45381 Certificat
